Scarica l'app Stockscreener
1.71
8.92%
0.14
Precedente Chiudi:
$1.57
Aprire:
$1.59
Volume 24 ore:
90,077
Relative Volume:
0.51
Capitalizzazione di mercato:
$169.19M
Reddito:
-
Utile/perdita netta:
$-60.14M
Rapporto P/E:
-2.4101
EPS:
-0.7095
Flusso di cassa netto:
$-68.17M
1 W Prestazione:
+1.79%
1M Prestazione:
+14.00%
6M Prestazione:
-46.39%
1 anno Prestazione:
-49.85%
Intervallo 1D:
$1.56
$1.745
Intervallo di 1 settimana:
$1.51
$1.78
Portata 52W:
$1.4299
$4.9782
Ac Immune Sa Stock (ACIU) Company Profile
Confronta ACIU con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
1.71 | 168.69M | 0 | -60.14M | -68.17M | -0.7095 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-31 | Iniziato | BTIG Research | Buy |
| 2019-02-01 | Downgrade | UBS | Buy → Neutral |
| 2019-01-04 | Iniziato | UBS | Buy |
| 2018-04-05 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2016-10-18 | Iniziato | Credit Suisse | Outperform |
| 2016-10-18 | Iniziato | Jefferies | Buy |
| 2016-10-18 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Ac Immune Sa Borsa (ACIU) Ultime notizie
AC Immune (NASDAQ:ACIU) Stock Rating Upgraded by StockNews.com - Defense World
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update - ADVFN
AC Immune (ACIU) to Release Earnings on Monday - Defense World
AC Immune’s Promising Pipeline and Strong Financial Position Justify Buy Rating - TipRanks
AC Immune (NASDAQ:ACIU) Downgraded by StockNews.com to “Hold” - Defense World
Equities Analysts Issue Forecasts for AC Immune Q2 Earnings - Defense World
FY2027 EPS Estimates for AC Immune Cut by HC Wainwright - Defense World
HC Wainwright Lowers AC Immune (NASDAQ:ACIU) Price Target to $12.00 - Defense World
Planning For Perseverance - Life Science Leader
AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates - MSN
AC Immune (ACIU) Stock Rating Maintained, Price Target Lowered | - GuruFocus
H.C. Wainwright cuts AC Immune SA target to $12; maintains buy - Investing.com
AC Immune (ACIU) Target Price Reduced by H.C. Wainwright | ACIU Stock News - GuruFocus
AC Immune price target lowered to $12 from $16 at H.C. Wainwright - TipRanks
AC Immune: Q1 Earnings Snapshot - MySA
AC Immune reports Q1 EPS (19c) vs (18c) last year - TipRanks
AC Immune Reports Q1 2025 Financial Results - TipRanks
ACIU Surpasses Revenue Expectations with Strong Phase 2 Data | A - GuruFocus
AC Immune SA Reports Q1 2025 Financial Results and Clinical Advancements in Neurodegenerative Disease Therapies - Nasdaq
AC Immune Q1 Results: Breakthrough in Parkinson's Treatment Shows Promise, Cash Runway Extended to 2027 - Stock Titan
Precision Prevention: The Latest on Alzheimer’s Vaccines - Being Patient
Renaissance Technologies LLC Has $2 Million Stock Position in AC Immune SA (NASDAQ:ACIU) - American Banking and Market News
Individual investors in AC Immune SA (NASDAQ:ACIU) are its biggest bettors, and their bets paid off as stock gained 11% last week - Yahoo Finance
Wells Fargo & Company MN Lowers Stock Holdings in AC Immune SA (NASDAQ:ACIU) - Defense World
Q2 Earnings Estimate for AC Immune Issued By Leerink Partnrs - Defense World
Q1 Earnings Estimate for AC Immune Issued By Leerink Partnrs - Defense World
AC Immune unveils first-in-class Morphomer targeting pathological α-synuclein - BioWorld MedTech
HC Wainwright Reiterates “Buy” Rating for AC Immune (NASDAQ:ACIU) - Defense World
AC Immune SA: Promising Phase 2 Results and Positive Outlook Drive Buy Rating - TipRanks
AC Immune reports interim outcomes from trial of Parkinson’s therapy - Yahoo Finance
AC Immune (ACIU) Shares Surge on Promising Parkinson's Trial Res - GuruFocus
AC Immune reports Phase II trial of ACI-7104.056 - The Pharma Letter
AC Immune’s Strategic Advances and Financial Highlights - TipRanks
AC Immune Announces Positive Interim Data From Early Parkinson's Disease Study - Nasdaq
AC Immune stock gains on Parkinson’s data (ACIU:NASDAQ) - Seeking Alpha
AC Immune announces additional data from Phase 2 study of VacSYn clinical trial - TipRanks
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease - The Manila Times
AC Immune SAACI-7104.056 Is Well Tolerated With No Safety Issues Reported To Date - MarketScreener
AC Immune Reports Further Positive Interim Results from - GlobeNewswire
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease - Yahoo
Benign Growth For AC Immune SA (NASDAQ:ACIU) Underpins Stock's 26% Plummet - simplywall.st
Short Interest in AC Immune SA (NASDAQ:ACIU) Rises By 23.9% - Defense World
AC Immune To Showcase Innovations In Active Immunotherapies - Evrim Ağacı
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 - GlobeNewswire
AC Immune SA to Highlight Advanced Immunotherapy Pipeline at AD/PD™ 2025 Conference - Nasdaq
Ac Immune Sa Azioni (ACIU) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.54%
7.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):